Sarepta Therapeutics
Stock Forecast, Prediction & Price Target

Sarepta Therapeutics (SRPT) stock Price Target by analysts

Last Year
Average Price Target

$181.8

Potential upside: 818.18%

Based on 5 analysts

Sarepta Therapeutics price prediction

Strike.market

What is Sarepta Therapeutics stock analysts` prediction?

Sarepta Therapeutics stock forecast: Based on 5 Wall Street analysts` predicted price targets for Sarepta Therapeutics in the last 3 months, the avarage price target is $181.8, with a high forecast of $NaN. The average price target represents a 818.18% change from the last price of $19.8.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Sarepta Therapeutics stock Price Target by analysts

Full breakdown of analysts given Sarepta Therapeutics price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Gil Blum
Needham
0%
0/3
9 months ago $202 920.20% upside $136.87 StreetInsider
Previous targets (2)
Biren Amin
Piper Sandler
0%
0/4
9 months ago $182 819.19% upside $136.87 StreetInsider
Previous targets (3)
Brian Skorney
Robert W. Baird
0%
0/3
10 months ago $193 874.74% upside $124.95 StreetInsider
Previous targets (2)
Kristen Kluska
Cantor Fitzgerald
0%
0/1
10 months ago $167 743.43% upside $124.95 StreetInsider
Previous targets (0)
Andrew Tsai
Jefferies
0%
0/1
11 months ago $165 733.33% upside $127.08 StreetInsider
Previous targets (0)
Gavin Clark-Gartner
Evercore ISI
0%
0/2
about 1 year ago $179 804.04% upside $136.4 StreetInsider
Previous targets (1)
Biren Amin
Piper Sandler
0%
0/4
about 1 year ago $200 910.10% upside $140.06 TheFly
Previous targets (3)
Brian Abrahams
RBC Capital
0%
0/5
about 1 year ago $181 814.14% upside $140.06 StreetInsider
Previous targets (4)
Gena Wang
Barclays
0%
0/2
about 1 year ago $203 925.25% upside $140.06 TheFly
Previous targets (1)
Brian Abrahams
RBC Capital
0%
0/5
about 1 year ago $182 819.19% upside $147.88 StreetInsider
Previous targets (4)
Kostas Biliouris
BMO Capital
0%
0/2
about 1 year ago $200 910.10% upside $154.79 StreetInsider
Previous targets (1)
Biren Amin
Piper Sandler
0%
0/4
about 1 year ago $205 935.35% upside $156.91 StreetInsider
Previous targets (3)
Gavin Clark-Gartner
Evercore ISI
0%
0/2
about 1 year ago $185 834.34% upside $160.72 TheFly
Previous targets (1)
Uy Ear
Mizuho Securities
0%
0/3
about 1 year ago $200 910.10% upside $165.13 StreetInsider
Previous targets (2)
Brian Skorney
Robert W. Baird
0%
0/3
about 1 year ago $200 910.10% upside $171.35 StreetInsider
Previous targets (2)
Gena Wang
Barclays
0%
0/2
about 1 year ago $185 834.34% upside $119.98 TheFly
Previous targets (1)
Brian Skorney
Robert W. Baird
0%
0/3
about 1 year ago $170 758.58% upside $124 TheFly
Previous targets (2)
Biren Amin
Piper Sandler
0%
0/4
about 1 year ago $157 692.92% upside $119.98 StreetInsider
Previous targets (3)
Kostas Biliouris
BMO Capital
0%
0/2
about 1 year ago $170 758.58% upside $117.44 StreetInsider
Previous targets (1)
Brian Abrahams
RBC Capital
0%
0/5
over 1 year ago $142 617.17% upside $123.46 StreetInsider
Previous targets (4)
Brian Abrahams
RBC Capital
0%
0/5
over 1 year ago $157 692.92% upside $130.7 TheFly
Previous targets (4)
Uy Ear
Mizuho Securities
0%
0/3
over 1 year ago $179 804.04% upside $132.74 StreetInsider
Previous targets (2)
Hartaj Singh
Oppenheimer
33.33%
1/3
over 1 year ago $180 809.09% upside $131.7 StreetInsider
Previous targets (2)
Matthew Harrison
Morgan Stanley
0%
0/2
over 1 year ago $165 733.33% upside $135.04 StreetInsider
Previous targets (1)
Brian Abrahams
RBC Capital
0%
0/5
over 1 year ago $141 612.12% upside $130.9 StreetInsider
Previous targets (4)
Matthew Harrison
Morgan Stanley
0%
0/2
over 2 years ago $187 844.44% upside $145.01 Benzinga
Previous targets (1)
Unknown
Credit Suisse
N/A
over 2 years ago $114 475.75% upside $117.53 Benzinga
N/A
Unknown
Needham
N/A
over 2 years ago $160 708.08% upside $117.53 Benzinga
N/A
Unknown
BTIG
N/A
over 2 years ago $160 708.08% upside $132.13 Benzinga
N/A
Unknown
UBS
N/A
over 2 years ago $158 697.97% upside $123.56 Benzinga
N/A
Gil Blum
Needham
0%
0/3
almost 3 years ago $158 697.97% upside $105.01 TipRanks Contributor
Previous targets (2)
Unknown
Morgan Stanley
N/A
almost 3 years ago $135 581.81% upside $116.57 Benzinga
N/A
Hartaj Singh
Oppenheimer
33.33%
1/3
about 3 years ago $150 657.57% upside $109 Pulse 2.0
Previous targets (2)
Unknown
Morgan Stanley
N/A
about 3 years ago $100 405.05% upside $95.2 Benzinga
N/A
Unknown
Needham
N/A
about 3 years ago $162 718.18% upside $93.96 Benzinga
N/A
Unknown
Morgan Stanley
N/A
about 3 years ago $80 304.04% upside $84.04 Benzinga
N/A
Unknown
Goldman Sachs
N/A
over 3 years ago $155 682.82% upside $68.84 Benzinga
N/A
Zhiqiang Shu
Berenberg Bank
100%
1/1
over 3 years ago $94 374.74% upside $79.56 TipRanks Contributor
Previous targets (0)
Gil Blum
Needham
0%
0/3
over 3 years ago $150 657.57% upside $79.56 TipRanks Contributor
Previous targets (2)
Uy Ear
Mizuho Securities
0%
0/3
over 3 years ago $160 708.08% upside $76.15 TipRanks Contributor
Previous targets (2)
Yun Zhong
BTIG
100%
1/1
over 3 years ago $125 531.31% upside $84.09 TipRanks Contributor
Previous targets (0)
Hartaj Singh
Oppenheimer
33.33%
1/3
over 3 years ago $125 531.31% upside $89.16 StreetInsider
Previous targets (2)
Judah Frommer
Credit Suisse
100%
1/1
almost 4 years ago $95 379.79% upside $84.19 TheFly
Previous targets (0)

Sarepta Therapeutics Financial Estimates

Sarepta Therapeutics Revenue Estimates

Sarepta Therapeutics EBITDA Estimates

Sarepta Therapeutics Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$701.88M
 
N/A
$933.01M
 
32.92%
$1.24B
 
33.26%
Avg: $3.12B
Low: $2.31B
High: $4.11B
avg. 151.19%
Avg: $3.71B
Low: $2.97B
High: $4.69B
avg. 19.07%
Avg: $4.31B
Low: $3.45B
High: $5.44B
avg. 16.04%
Avg: $4.62B
Low: $3.70B
High: $5.82B
avg. 7.10%
Net Income
 
% change YoY
$-418.78M
 
N/A
$-703.48M
 
-67.98%
$-535.97M
 
23.81%
Avg: $994.29M
Low: $48.04M
High: $1.78B
avg. 285.51%
Avg: $1.32B
Low: $108.10M
High: $2.00B
avg. 33.60%
Avg: $1.44B
Low: $1.07B
High: $1.94B
avg. 9.02%
Avg: $1.62B
Low: $1.20B
High: $2.17B
avg. 11.99%
EBITDA
 
% change YoY
$-412.11M
 
N/A
$-473.53M
 
-14.90%
$-439.19M
 
7.25%
Avg: $-2.05B
Low: $-2.70B
High: $-1.52B
avg. -367.91%
Avg: $-2.44B
Low: $-3.08B
High: $-1.96B
avg. -19.07%
Avg: $-2.83B
Low: $-3.58B
High: $-2.27B
avg. -16.04%
Avg: $-3.04B
Low: $-3.83B
High: $-2.43B
avg. -7.10%
EPS
 
% change YoY
-$5.15
 
N/A
-$8.03
 
-55.92%
-$5.8
 
27.77%
Avg: $11.35
Low: $0.52
High: $19.36
avg. 295.65%
Avg: $12.8
Low: $1.17
High: $21.66
avg. 12.79%
Avg: $15.68
Low: $11.62
High: $21
avg. 22.46%
Avg: $17.56
Low: $13.02
High: $23.52
avg. 11.99%
Operating Expenses
 
% change YoY
$1.05B
 
N/A
$1.32B
 
26.04%
$1.36B
 
2.37%
Avg: $1.63B
Low: $1.21B
High: $2.14B
avg. 19.82%
Avg: $1.94B
Low: $1.55B
High: $2.44B
avg. 19.07%
Avg: $2.25B
Low: $1.80B
High: $2.84B
avg. 16.04%
Avg: $2.41B
Low: $1.93B
High: $3.04B
avg. 7.10%

FAQ

What is Sarepta Therapeutics stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 85.03% in 2025-2028.

We have gathered data from 12 analysts. Their low estimate is 48.04M, average is 994.29M and high is 1.78B.

What is Sarepta Therapeutics stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 48.35% in 2025-2028.

We have gathered data from 14 analysts. Their low revenue estimate is $2.31B, average is $3.12B and high is $4.11B.

What is Sarepta Therapeutics stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 85.72% in 2025-2028.

We have gathered data from 12 analysts. Their low earnings per share estimate is $0.52, average is $11.35 and high is $19.36.

What is the best performing analyst?

In the last twelve months 5 analysts have been covering Sarepta Therapeutics stock. The most successful analyst is Gil Blum.